Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen Idec buys Neurimmune immunotherapy programmes

Biogen Idec buys Neurimmune immunotherapy programmes

22nd December 2010

Biogen Idec has agreed a deal to take control of three pre-clinical immunotherapy programmes initiated by Neurimmune Holding.

The company has acquired the subsidiary of Neurimmune responsible for the projects, which focus on the discovery and development of human antibodies addressing three important central nervous system targets.

Biogen Idec will now take full responsibility for the further development and commercialisation of any drug products created by these programmes, which are believed to have potential in addressing conditions such as Parkinson's and Alzheimer's disease.

This builds on an existing research partnership between the two companies in the area of human antibodies, which has been in effect since 2007.

Dr Alfred Sandrock, senior vice-president for neurology research and development at Biogen Idec, said: "The unmet medical need among patients suffering from devastating neurodegenerative diseases is high and we are excited to be moving these three promising programmes forward."

Earlier this month, the company announced that it will be providing a series of grants to US medical centres and universities in order to support research into multiple sclerosis.ADNFCR-8000103-ID-800306180-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.